Showing 2683 results
-
Key Release /PARAGON study narrowly misses statistical significance on the primary endpoint; overall safety profile confirmed Totality of evidence suggests potential clinically important benefit; results will…
-
Press Release /Lucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants Positive opinion is based on the landmark…
-
Press Release /Basel, August 6, 2019 – Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma® (onasemnogene abeparvovec-xioi). First and…
-
Press Release /In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant improvement in overall survival in post-menopausal women in first- and second-line setting Kisqali is the only CDK4/6…
-
Press Release /PARAGON-HF trial will provide Entresto® (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF)[1] New PROVE-HF and EVALUATE-HF studies will…
-
Press Release /Sandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit Ruling prevents launch of important, affordable treatment option for US patients affected by chronic…
-
Press Release /Entresto (sacubitril/valsartan) reduced the composite of total (first and recurrent) heart failure hospitalizations and cardiovascular death although narrowly missed statistical significance (p = 0.…
-
Key Release /In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio®* (teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary…
-
Press Release /Worldwide agreement with Polpharma Biologics gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS) RRMS affects ~85% of MS…
-
Press Release /Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients[1…